Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Mutationally Activated TYK2 From T-ALL Specimens Exhibits Tranformative Capacity in Cell Lines and Primary Cell Models and T-Lineage Expansion in Mice

Angela G. Fleischman, MD, PhD, Takaomi Sanda, MD, PhD, Alejandro Gutierrez, MD, Samuel B Luty, Stephanie G Willis, A. Thomas Look, M.D., Brian J. Druker, Jeffrey W Tyner, PhD

Blood (2011) 118 (21): 74.

https://doi.org/10.1182/blood.V118.21.74.74

Published: 2011

Journal Articles

Pathway Dependence on the Tyrosine Kinase TYK2 and Its Mediator STAT1 In T-Cell Acute Lymphoblastic Leukemia

Takaomi Sanda, MD, PhD, Jeffrey W Tyner, PhD, Alejandro Gutierrez, MD, Vu N Ngo, PhD, Richard Moriggl, Yebin Ahn, Jason M Glover, MD, Bill H Chang, MD, PhD, Stephanie G Willis, Louis M. Staudt, MD, PhD, Brian J Druker, MD, A. Thomas Look, MD

Blood (2010) 116 (21): 3155.

https://doi.org/10.1182/blood.V116.21.3155.3155

Published: 2010

Journal Articles

RNAi Screen Reveals TYK2 as a Novel Therapeutic Gene Target In T-Cell Acute Lymphoblastic Leukemia

Jeffrey W Tyner, PhD, Takaomi Sanda, MD, PhD, Alejandro Gutierrez, MD, Jason M Glover, MD, Bill H Chang, MD, PhD, Stephanie G Willis, Yebin Ahn, A. Thomas Look, MD, Brian J Druker, MD

Blood (2010) 116 (21): 1001.

https://doi.org/10.1182/blood.V116.21.1001.1001

Published: 2010

Journal Articles

A gene expression signature of CD34 + cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib

Shannon K. McWeeney, Lucy C. Pemberton, Marc M. Loriaux, Kristina Vartanian, Stephanie G. Willis, Gregory Yochum, Beth Wilmot, Yaron Turpaz, Raji Pillai, Brian J. Druker, Jennifer L. Snead, Mary MacPartlin, Stephen G. O'Brien, Junia V. Melo, Thoralf Lange, Christina A. Harrington, Michael W. N. Deininger

Blood (2010) 115 (2): 315–325.

https://doi.org/10.1182/blood-2009-03-210732

Published: 2010

Includes: Supplemental data

Journal Articles

Mutational Analysis of BCR-Abl From Subjects with Relapsed Ph+ALL Treated On the COG Protocol AALL0031: a Report From the Children's Oncology Group.

Bill H Chang, MD, PhD, Stephanie G Willis, Linda C. Stork, MD, Stephen P Hunger, MD, William L. Carroll, MD, Bruce Camitta, MD, Naomi J. Winick, MD, Brian J. Druker, MD, Kirk R. Schultz, MD

Blood (2009) 114 (22): 2634.

https://doi.org/10.1182/blood.V114.22.2634.2634

Published: 2009

Journal Articles

A Gene Expression Signature of CD34+ Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance.

Shannon McWeeney, Gregory Yochum, Lucy C. Pemberton, MD, FRCPath, Marc Loriaux, MD, PhD, Kristina Vartanian, Stephanie G Willis, Beth Wilmot, Yaron Turpaz, Raji Pillai, Mary Mac partlin, Jennifer Snead, PhD, Brian J. Druker, MD, Stephen G O'Brien, MD, PhD, Junia V. Melo, MD, PhD, Thoralf Lange, MD, Christina Harrington, Michael Deininger, MD, PhD

Blood (2009) 114 (22): 508.

https://doi.org/10.1182/blood.V114.22.508.508

Published: 2009

Journal Articles

RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies.

Jeffrey W Tyner, PhD, Marc Loriaux, MD, PhD, Stephanie G Willis, Bill H Chang, MD, PhD, Vincent T Bicocca, Stephen T Oh, MD, PhD, Iris H.I.M. Hollink, MD, Stefanie Segers, Monique L. DenBoer, MSc, PhD, Marry M van den Heuvel-Eibrink, MD, PhD, C. Michel Zwaan, MD, PhD, Jason R Gotlib, MD, MS, Michael Deininger, MD, PhD, Brian J. Druker, MD

Blood (2009) 114 (22): 3978.

https://doi.org/10.1182/blood.V114.22.3978.3978

Published: 2009

Journal Articles

Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib

Richard D. Press, Stephanie G. Willis, Jennifer Laudadio, Michael J. Mauro, Michael W. N. Deininger

Blood (2009) 114 (13): 2598–2605.

https://doi.org/10.1182/blood-2008-08-173674

Published: 2009

Journal Articles

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients

Jeffrey W. Tyner, Heidi Erickson, Michael W. N. Deininger, Stephanie G. Willis, Christopher A. Eide, Ross L. Levine, Michael C. Heinrich, Norbert Gattermann, D. Gary Gilliland, Brian J. Druker, Marc M. Loriaux

Blood (2009) 113 (8): 1749–1755.

https://doi.org/10.1182/blood-2008-04-152157

Published: 2009

Includes: Supplemental data

Journal Articles

Determining the Rise in BCR-ABL RNA That Optimally Predicts a Kinase Domain Mutation in Patients with CML on Imatinib.

Richard D. Press, MD, PhD, Stephanie G Willis, Jennifer Laudadio, Michael J. Mauro, MD, Michael W.N. Deininger, MD

Blood (2008) 112 (11): 1108.

https://doi.org/10.1182/blood.V112.11.1108.1108

Published: 2008

Journal Articles

RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Leukemia Patients

Jeffrey W Tyner, PhD, Marc Loriaux, MD, PhD, Stephanie G Willis, Bill Chang, MD, PhD, Vincent T Bicocca, Stephen Oh, MD, PhD, Iris H.I.M. Hollink, MD, Stefanie Segers, Monique L. den Boer, C. M Zwaan, MD, PhD, Jason R. Gotlib, Michael W.N. Deininger, MD, Brian J. Druker

Blood (2008) 112 (11): 758.

https://doi.org/10.1182/blood.V112.11.758.758

Published: 2008

Journal Articles

Absence of SKP2 expression attenuates BCR-ABL–induced myeloproliferative disease

Anupriya Agarwal, Thomas G. P. Bumm, Amie S. Corbin, Thomas O'Hare, Marc Loriaux, Jonathan VanDyke, Stephanie G. Willis, Jutta Deininger, Keiichi I. Nakayama, Brian J. Druker, Michael W. Deininger

Blood (2008) 112 (5): 1960–1970.

https://doi.org/10.1182/blood-2007-09-113860

Published: 2008

Includes: Supplemental data

Journal Articles

RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia

Jeffrey W. Tyner, Denise K. Walters, Stephanie G. Willis, Mary Luttropp, Jason Oost, Marc Loriaux, Heidi Erickson, Amie S. Corbin, Thomas O'Hare, Michael C. Heinrich, Michael W. Deininger, Brian J. Druker

Blood (2008) 111 (4): 2238–2245.

https://doi.org/10.1182/blood-2007-06-097253

Published: 2008

Includes: Supplemental data

Journal Articles

Identification of Tyrosine Kinase Mutations by Large-Scale DNA Sequencing in Patients with Chronic Myelomonocytic Leukemia/Atypical Chronic Myeloid Leukemia.

Jeffrey W. Tyner, PhD, Christopher A. Eide, BA, Eric P. Stoffregen, BS, Marc Loriaux, MD, Stephanie G. Willis, BS, Norbert Gattermann, PhD, Tibor Kovacsovics, MD, Brian J. Druker, MD, Michael W. Deininger, MD,PhD

Blood (2006) 108 (11): 3606.

https://doi.org/10.1182/blood.V108.11.3606.3606

Published: 2006

Journal Articles

The F-Box Protein Skp2 Regulates Expression of p27 in BCR-ABL Transformed Cell Lines and Is Required for Induction of Myeloproliferative Disease in a Murine Model.

Anupriya Agarwal, PhD, Thomas G.P. Bumm, MD, Amie Corbin, Thomas O’Hare, PhD, Marc Loriaux, MD, PhD, Stephanie G. Willis, Jutta Deininger, MD, Brian J. Druker, MD, Michael W.N. Deininger, MD, PhD

Blood (2006) 108 (11): 742.

https://doi.org/10.1182/blood.V108.11.742.742

Published: 2006

Journal Articles

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N -ethyl- N -nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations

Heather A. Bradeen, Christopher A. Eide, Thomas O'Hare, Kara J. Johnson, Stephanie G. Willis, Francis Y. Lee, Brian J. Druker, Michael W. Deininger

Blood (2006) 108 (7): 2332–2338.

https://doi.org/10.1182/blood-2006-02-004580

Published: 2006

Includes: Supplemental data

Journal Articles

A Gene Polymorphism within the Kinase Domain of BCR-ABL and Its Effects on Sensitivity to Tyrosine Kinase Inhibitors.

Lucy C. Crossman, MD, Thomas O’Hare, PhD, Thoralf Lange, MD, Stephanie G. Willis, Eric P. Stoffregen, Amie S. Corbin, Stephen G. O’Brien, MD, PhD, Michael C. Heinrich, MD, Brian J. Druker, MD, Peter G. Middleton, PhD, Michael W.N. Deininger, MD, PhD

Blood (2005) 106 (11): 1530.

https://doi.org/10.1182/blood.V106.11.1530.1530

Published: 2005

Journal Articles

Comparison of Imatinib, AMN107 and Dasatinib in an Accelerated Cell-Based Mutagenesis Screen.

Michael W.N. Deininger, MD, PhD, Heather Bradeen, MD, Taiping Jia, Thomas O’Hare, PhD, Stephanie G. Willis, Frank Lee, PhD, Brian J. Druker, MD

Blood (2005) 106 (11): 691.

https://doi.org/10.1182/blood.V106.11.691.691

Published: 2005

Journal Articles

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

Blood (2005) 106 (10): 3377–3379.

https://doi.org/10.1182/blood-2005-05-1898

Published: 2005

Journal Articles

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

Stephanie G. Willis, Thoralf Lange, Shadmehr Demehri, Sandra Otto, Lucy Crossman, Dietger Niederwieser, Eric P. Stoffregen, Shannon McWeeney, Ines Kovacs, Byung Park, Brian J. Druker, Michael W. Deininger

Blood (2005) 106 (6): 2128–2137.

https://doi.org/10.1182/blood-2005-03-1036

Published: 2005

NARROW

Mutationally Activated TYK2 From T-ALL Specimens Exhibits Tranformative Capacity in Cell Lines and Primary Cell Models and T-Lineage Expansion in Mice

Pathway Dependence on the Tyrosine Kinase TYK2 and Its Mediator STAT1 In T-Cell Acute Lymphoblastic Leukemia

RNAi Screen Reveals TYK2 as a Novel Therapeutic Gene Target In T-Cell Acute Lymphoblastic Leukemia

A gene expression signature of CD34 + cells to predict major cytogenetic response in chronic-phase chronic myeloid leukemia patients treated with imatinib

Mutational Analysis of BCR-Abl From Subjects with Relapsed Ph+ALL Treated On the COG Protocol AALL0031: a Report From the Children's Oncology Group.

A Gene Expression Signature of CD34+ Cells to Predict Major Cytogenetic Response in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Imatinib: Potential Involvement of Beta-Catenin in Drug Resistance.

RAPID siRNA Screen for Identification of Therapeutic Gene Targets in Patients with Hematologic Malignancies.

Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients

Determining the Rise in BCR-ABL RNA That Optimally Predicts a Kinase Domain Mutation in Patients with CML on Imatinib.

RNAi Screening of the Tyrosine Kinome Identifies Therapeutic Targets in Leukemia Patients

Absence of SKP2 expression attenuates BCR-ABL–induced myeloproliferative disease

RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia

Identification of Tyrosine Kinase Mutations by Large-Scale DNA Sequencing in Patients with Chronic Myelomonocytic Leukemia/Atypical Chronic Myeloid Leukemia.

The F-Box Protein Skp2 Regulates Expression of p27 in BCR-ABL Transformed Cell Lines and Is Required for Induction of Myeloproliferative Disease in a Murine Model.

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N -ethyl- N -nitrosourea (ENU)–based mutagenesis screen: high efficacy of drug combinations

A Gene Polymorphism within the Kinase Domain of BCR-ABL and Its Effects on Sensitivity to Tyrosine Kinase Inhibitors.

Comparison of Imatinib, AMN107 and Dasatinib in an Accelerated Cell-Based Mutagenesis Screen.

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only